Full Breakdown
Eli Lilly’s $3.8-$4 Billion Push into Vaccine Development
5/26/2026, 9:07:03 PM
Acquisition Overview
On May 26, 2026 Eli Lilly agreed to buy Curevo Inc., LimmaTech Biologics AG and Vaccine Company Inc. for up to $3.8-$4 billion in cash, including upfront and milestone payments. The deals bring Curevo’s shingles vaccine amezosvatein, LimmaTech’s LTB-SA7 bacterial vaccine, and Vaccine Company’s IVN platform for an EBV vaccine. Shares rose 0.9 %.
Context and Rationale
The moves follow a cash surge from Lilly’s blockbuster obesity and type-2 diabetes drugs—Mounjaro, Zepbound and GLP-1 pill Foundayo—each generating over $4 billion in U.S. Q1 revenue. After years away from infectious-disease R&D, the firm is re-entering to tackle antimicrobial resistance and long-term viral risks.
Principal Entities
Eli Lilly, led by chief scientific and product officer Daniel M. Skovronsky, will acquire Curevo (Seattle-area shingles vaccine amezosvatein), LimmaTech Biologics (Swiss bacterial-vaccine platform with LTB-SA7 in Phase I) and Vaccine Company (preclinical IVN platform for an EBV vaccine). Carnegie Investment Counsel’s Shams Afzal commented on the deals.
Data & Statistics
Deal values are $1.5 bn (Curevo), $780 m (LimmaTech) and $1.55 bn (Vaccine Company). Lilly holds 60.1 % of the U.S. obesity-drug market; Novo Nordisk 39.4 %.
Strategic Significance
The acquisitions give Lilly early-stage vaccine platforms against viral and bacterial threats, addressing antimicrobial resistance and long-term disease risks while supporting Lilly’s diversification of its pipeline.
Official Statements & Responses
Lilly said the purchases reflect a deliberate strategy to prevent disease at its source. Analysts view the price as modest and note the hiring of former FDA official Peter Marks. The company also highlighted its strong cash position. Transactions await antitrust clearance.
Criticism & Opposition
Critics note none of the targets have marketed products, raising execution risk, and warn the large cash spend occurs amid a slowdown in vaccine financing.
Conflicting Reports & Gaps
Sources differ on the total value—$3.8 bn, $3.83 bn or “almost $4 bn.” Curevo’s candidate is called amezosvatein or CRV-101. LimmaTech’s platform is described as targeting bacterial pathogens or toxins and superantigens. No timeline is given.
Verbatim Quotes
- “These acquisitions reflect a deliberate strategy to prevent disease at its source rather than treat its consequences.” — Daniel M. Skovronsky, chief scientific and product officer, Eli Lilly
- “The bite-sized price tag in the overall scheme of things certainly helps,” — Shams Afzal, managing director, Carnegie Investment Counsel
- “Decades of evidence now link common infections to diseases that potentially emerge years later, including neurological disease, cancer and infertility.” — Daniel M. Skovronsky, Eli Lilly
- “As antimicrobial resistance erodes our ability to treat bacterial infections, vaccines are increasingly the only path to prevention.” — Daniel M. Skovronsky, Eli Lilly
What’s Next
Lilly will monitor milestone payments tied to amezosvatein’s Phase III readout, LTB-SA7’s Phase II progress and the EBV vaccine’s Phase I start. Integration is planned for H2 2026, pending antitrust approval.
